Obstructive hypertrophic cardiomyopathy (obstructive HCM) is a form of heart disease where thickened heart muscle physically blocks blood from flowing out of the heart’s main pumping chamber. About 1 in 500 adults worldwide has hypertrophic cardiomyopathy, and roughly one-third of those patients develop significant obstruction, either at rest or during physical activity. The obstruction makes the heart work harder to push blood to the body, which is why breathlessness during exertion is the most common symptom.
How the Obstruction Happens
In a normal heart, the left ventricle contracts and pushes blood through a wide channel called the left ventricular outflow tract (LVOT) before it reaches the aorta and the rest of the body. In obstructive HCM, two things go wrong at once. First, the wall of muscle separating the heart’s chambers (the septum) grows abnormally thick, narrowing that outflow channel. Second, the narrowed channel changes blood flow patterns in a way that pulls one of the mitral valve’s leaflets forward during each heartbeat, a phenomenon called systolic anterior motion. That displaced leaflet acts like a partial dam, further blocking blood flow right when the heart is trying to pump.
This obstruction is “dynamic,” meaning it changes from moment to moment. Anything that makes the heart squeeze harder or faster, or that reduces the volume of blood inside the ventricle, worsens the blockage. That’s why symptoms often flare during exercise, dehydration, or standing up quickly, and may be barely noticeable at rest.
Common Symptoms
Shortness of breath during exertion is the hallmark complaint. Because the obstruction limits how much blood the heart can push out per beat, the body can’t get enough oxygen-rich blood during activity. Many people also experience chest pain, lightheadedness, or a sensation of the heart racing or pounding. Some notice they feel worse in hot weather or after meals, both of which can reduce blood volume or redirect it away from the heart.
Fainting or near-fainting episodes deserve special attention. They can signal that the obstruction is severe enough to temporarily starve the brain of blood, or they may point to an abnormal heart rhythm triggered by the thickened muscle. Not everyone with obstructive HCM has noticeable symptoms, though. Some people are diagnosed only after a heart murmur is heard on a routine exam or a family member is found to have the condition.
How It’s Diagnosed
An echocardiogram (ultrasound of the heart) is the primary tool. It shows the thickness of the heart walls and measures the pressure difference across the outflow tract, reported as a gradient in millimeters of mercury (mmHg). A peak gradient of 30 mmHg or higher at rest confirms obstruction. Treatment to reduce that gradient is typically recommended once it reaches 50 mmHg or above.
Because the obstruction is dynamic, resting measurements can underestimate the problem. Doctors often provoke the obstruction during the echo by asking you to perform a Valsalva maneuver (bearing down as if straining), squat, or stand up from a lying position. During peak stress testing, blood flow velocities through the outflow tract in HCM patients can reach 4.3 meters per second, more than double the speed in a normal heart, reflecting severe obstruction. Normal heart walls measure 12 mm or less. In HCM, thickness can range from mild (13 to 15 mm) to massive (over 30 mm), and a wall thickness of 30 mm or greater is considered a major risk factor for dangerous heart rhythms.
Medication Options
First-line treatment has traditionally involved beta-blockers or calcium channel blockers. These medications slow the heart rate and reduce how forcefully the heart contracts, which gives the ventricle more time to fill with blood and lessens the severity of the obstruction.
A newer class of medication, cardiac myosin inhibitors, targets the problem more directly. Mavacamten, the first drug in this class, works by reducing the number of molecular motors in the heart muscle that are available to generate force during each contraction. Instead of broadly slowing the heart, it dials down the excessive squeezing power at the protein level, keeping more of the muscle’s contractile units in a resting state so they can’t contribute to the obstruction.
Clinical trial results have been significant. In the EXPLORER-HCM trial, 37% of patients on mavacamten met the primary goal of improved exercise capacity and reduced symptoms, compared with 17% on placebo. In the VALOR-HCM trial, which enrolled patients who were otherwise headed for surgery, only about 9% ultimately needed a surgical procedure after starting the medication. These results have made cardiac myosin inhibitors a meaningful alternative for many patients who previously had limited options between beta-blockers and the operating room.
Surgical and Procedural Options
When medications don’t adequately control symptoms, two procedures can physically reduce the thickness of the septum to widen the outflow tract.
Septal myectomy is open-heart surgery in which a surgeon removes a small portion of the thickened septal muscle. It has been the gold standard for decades. In a large study of nearly 3,900 patients across three specialized centers, early mortality after myectomy was 0.3%, and the 10-year all-cause mortality rate was 8.2%.
Alcohol septal ablation is a catheter-based alternative. A small amount of alcohol is injected into the artery feeding the thickened portion of the septum, causing a controlled, localized area of muscle to thin out over time. It avoids open-heart surgery, but comes with trade-offs. Early mortality in the same large study was 0.7%, and the 10-year all-cause mortality rate was 26.1%. Even after adjusting for age, sex, and other health conditions, patients who had ablation had a 68% higher long-term mortality risk compared to those who had myectomy. Ablation also carries higher rates of needing a permanent pacemaker afterward and is more likely to leave a residual gradient.
Ablation is generally considered when a patient’s anatomy or overall health makes open-heart surgery too risky, or when surgery is declined. At experienced centers, myectomy remains the preferred option for most candidates.
Sudden Cardiac Death Risk
The thickened, disorganized heart muscle in HCM can serve as a trigger for dangerous heart rhythms. Several clinical markers help gauge this risk. A wall thickness of 30 mm or more is classified as a major risk factor. Other factors include a family history of sudden cardiac death from HCM, unexplained fainting, and documented episodes of abnormal heart rhythms on monitoring. When the overall risk is elevated, an implantable cardioverter-defibrillator (ICD) may be recommended. This small device continuously monitors heart rhythm and delivers a shock if a life-threatening arrhythmia occurs.
Exercise and Physical Activity
Guidelines on exercise in HCM have shifted considerably. For years, patients were told to avoid competitive sports and vigorous activity. More recent evidence has softened that stance. Prospective studies tracking HCM patients who continued competitive athletics found no increased risk of sudden cardiac death or dangerous arrhythmias compared with patients who withdrew from competition or exercised only moderately. One registry followed 259 competitive athletes with HCM, including 42 high school and college athletes, for more than three years and found no excess arrhythmic risk.
The 2024 guidelines from the American Heart Association and American College of Cardiology now recommend individualized, shared decision-making about sports participation rather than blanket restrictions. Decisions should be made with a clinician experienced in managing athletes with HCM and revisited at least once a year. The key factors include the severity of obstruction, symptom burden, and whether risk factors for sudden cardiac death are present.